In this issue:
NACT linked to poor survival in low-grade serous carcinomas
SORAYA results may change practice for FRα-high disease
Prevalence of occult high-grade carcinoma in BRCA1/2 mutation carriers
Obesity negatively impacts carboplatin dosing and survival
Atezolizumab not beneficial in BRCA1/2 mutated or HRD ovarian cancer
Clinical implications of tumour-based NGS
Delayed surgery and adjuvant treatment negatively effects survival
Relacorilant + nab-paclitaxel for platinum-resistant ovarian cancer
Molecular landscape in low-grade serous disease
Serum LAG-3 may be a predictive marker of outcomes in HGSOC
Adavosertib + carboplatin has activity in TP53 mutated disease
Please login below to download this issue (PDF)